Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Dec
31
Today In Oncology
Study Explores Association of GLP-1 RAs With Risk of Obesity-Related Cancers
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
Deb Schrag Elected 2027–2028 ASCO President
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo